Turning to the issue of resistance or relapse after MC, analysis of breast cancer patients treated with metronomic cyclophosphamide and capecitabine with fortnightly bevacizumab showed that relapse was associated with an increase in VEGF-A and low CEC counts, possibly suggestive of a switch to an alternative form of tumour vascularisation [46]. The gene discussed is VEGFA; the disease is neoplasm.